Hospital Universitario Nuestra Seora de Candelaria

Unidad de Investigacin
Neumology group
Ciro Casanova Macario
Ciro Casanova

Our Pulmonary Research Group initiated its activities in 1997 as part of the international multicenter study group named BODE. This group published in 2004 in the New England Journal of Medicine a study where the BODE index (a multidimensional clinical evaluator tool) was validated as the best predictor of COPD patients mortality. The main strength of this group is the long-term follow up period of a disease (COPD) with great relevance due to a high prevalence and considerable morbidity and mortality.
From the research lines that we have developed in the last decade, the following ones are still active:

  • Association of genetic variants of possible genetic markers for COPD and/or its phenotypes: COPD as muldimentional systemic disease could explain its clinical heterogeneity (phenotype), however this topic has not been fully studied. We evaluate whether certain variants in some cytokines genes (TNF-α, Lt-α, IL-6, IL-8) that contribute to airway inflammation, might be responsible of the clinical features diversity and prognostic of the disease.
  • Gender and COPD: The main goal of this study is to analyse gender differences in the presentation of COPD. Our hypothesis is that women may be affected in a different way with a greater impact in the perceptive as well systemic domains of the disease.
  • Biomarkers and COPD: We are evaluating the usefulness of serum biomarkers as important clinical predictors of the disease (C-reactive protein). We are analysing the prognostic value of a panel of biomarkers in a longitudinal cohort in relation to clinical parameters and pulmonary function.
  •  COPD and cardiovascular risk (CVR): we are studying new markers of vascular damage in COPD (microalbuminuria as a marker of endothelial dysfunction).  (25% of COPD patients die of cardiovascular events). We also evaluate the gene variants of the hypoxia inducible factor 1 (HIF-1A) and explore the utility of the carotid ultrasound scan in the early diagnostic of arterioesclerosis and its association with the CVR biomarkers.

In 2010, we are begining two new lines:

  • CHAIN (COPD History Assessement In SpaiN) study: we are the reference centre of a national multicentric study (50 hospitals) for the evaluation, in a large scale, of the multidimensional progression and phenotypic characterization  of COPD.
  • COPD and Senescence: COPD patients suffer an acelarated senescence. We will evaluate the  telomere length shorten and telomerase polymorphisms in our cohort (cross-sectional and longitudinal analysis) and its correlaction with  clinical parameters, pulmonary function and biomarkers. We will try to evaluate the role of the telomere length shorten as a marker of cardiovascular risk and cancer.